This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2004 Remove Hospitals Remove World Health Related Topics
Informed Consent COVID-19 Vaccine Public Health Governance Compliance FDA Licensing COVID-19 More Related Topics >
article thumbnail

SQA Regulatory Surveillance Summary 3 | Monthly Update 2021

SQA

APRIL 30, 2021

726/2004, 09 March 2021. 726/2004 , which essentially means duplicate MAAs for products authorized via the centralized procedure. World Health Organization (WHO). EC Issues Notice on the Handling of Duplicate Marketing Authorization Applications (MAAs) of Pharmaceutical Products under Article 82(1) of Regulation (EC) No.

COVID-19 Vaccine 52
COVID-19 Vaccine COVID-19 Compliance Governance 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – July and August 2023

SQA

OCTOBER 18, 2023

times the intended dose and required intervention in a hospital. After becoming aware of this medication error, Health Canada worked with the manufacturer to modify the product label (change from Calcium Carbonate 500 mg to Calcium 500 mg) to assist in reducing confusion and prevent similar incidents happening in the future.

FDA 40
FDA Compliance Licensing World Health 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 50,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024